Sipai Health Technology has restructured its executive leadership to align with the Corporate Governance Code. Effective November 20, 2026, Mr. Li Ji has been appointed as CEO, while Mr. Ma Xuguang transitions to the role of President while retaining his position as Chairman of the Board.
Mr. Ma Xuguang ceases to be CEO from November 20, 2026 and becomes President while remaining Chairman; Mr. Li Ji takes over as CEO. This is a role swap that brings the company into compliance with Corporate Governance Code Provision C.2.1 (separating Chairman and CEO roles). Both men remain executive Directors, confirmed no disagreement with the Board, and no shareholder matter was flagged, so fundamentals and leadership continuity are unchanged.
- • Effective November 20, 2026: Mr. Li Ji appointed CEO, Mr. Ma Xuguang becomes President while staying Chairman
- • Company states it is now in full compliance with Corporate Governance Code Provision C.2.1
- • Both executives jointly hold 104,280,000 shares, about 13.6% of issued share capital, so control is unchanged
- • No change in remuneration or strategy disclosed; announcement is procedural